Trial · NCT07903584
Personalized Drug Treatment of Frail Patients: Integrated Care and Real-Time Home Monitoring
NCT07903584, Not applicable, Completed, Istituti Clinici Scientifici Maugeri SpA
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Personalized Drug Treatment of Frail Patients: Integrated Care and Real-Time Home Monitoring. Trials, record NCT07903584. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07903584
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Personalized Drug Treatment of Frail Patients: Integrated Care and Real-Time Home Monitoring
- NCT number
- NCT07903584
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 40 participants, actual
- Lead sponsor
- Istituti Clinici Scientifici Maugeri SpA
- Conditions
- Frailty, Polypharmacy (People Under Treatment With 5 or More Drugs), Multimorbidity
- Interventions
- Healthcare device, Remote monitoring by Specialist Operations Centres, Blood drug concentration monitoring beyond routine TDM
- First posted
- 2026-10-29
- Last updated
- 2026-11-04
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in health-related quality of life (EQ-5D-5L) | Baseline (T0), 3 months (T1) and 6 months (T2) | Health-related quality of life assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. The questionnaire evaluates five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.For each dimension, patients select one of five response options, ranging from no problems to extreme problems or inability to perform the activity. Higher levels of reported problems indicate worse health status. The questionnaire also includes a self-rated health scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state), with higher scores indicating better perceived health. Assessments are performed at enrolment (T0), 3 months (T1), and 6 months (T2) |
| Secondary | Usability of the technological solution (System Usability Scale) | Baseline (T0), 3 months (T1) and 6 months (T2) | Usability assessed using the System Usability Scale (SUS), a 10-item questionnaire completed by patients and caregivers. The total SUS score ranges from 0 to 100, with higher scores indicating better perceived usability of the technological solution. |
| Secondary | Adherence to therapy (MARS-5) | 3 months (T1) and 6 months (T2) | Medication adherence assessed using the Medication Adherence Report Scale (MARS-5), a 5-item questionnaire. The total score ranges from 5 to 25, with higher scores indicating better medication adherence. |
| Secondary | Number of critical clinical events intercepted | From enrolment to 6 months | Medication adherence assessed using the Medication Adherence Report Scale (MARS-5), a 5-item questionnaire. The total score ranges from 5 to 25, with higher scores indicating better medication adherence. |
| Secondary | Number of potentially dangerous events detected by drug level measurement | From enrolment to 6 months | Events found through blood drug concentrations that led to corrective interventions (e.g. toxic levels, interactions, inefficacy). |
| Secondary | Blood drug levels | Baseline, 3 months and 6 months | Measurement of blood concentrations of selected medications prescribed at hospital discharge, expressed in μg/L, at baseline, 3 and 6 months after enrolment, and whenever clinically necessary. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers10
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07903584
GET https://conductscience.org/api/trials/v1/NCT07903584/registered